MedKoo Cat#: 597862 | Name: Enalapril
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Enalapril is an angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.

Chemical Structure

Enalapril
Enalapril
CAS#75847-73-3 (free acid)

Theoretical Analysis

MedKoo Cat#: 597862

Name: Enalapril

CAS#: 75847-73-3 (free acid)

Chemical Formula: C20H28N2O5

Exact Mass: 376.1998

Molecular Weight: 376.45

Elemental Analysis: C, 63.81; H, 7.50; N, 7.44; O, 21.25

Price and Availability

Size Price Availability Quantity
250mg USD 350.00 2 Weeks
500mg USD 550.00 2 Weeks
1g USD 950.00 2 Weeks
2g USD 1,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Enalapril; Enarenal; Enalaprila; Enalaprilum; Enalapril Richet; Gadopril; Kinfil; Bonuten;
IUPAC/Chemical Name
((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-L-proline
InChi Key
GBXSMTUPTTWBMN-XIRDDKMYSA-N
InChi Code
InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
SMILES Code
O=C(O)[C@H]1N(C([C@H](C)N[C@H](C(OCC)=O)CCC2=CC=CC=C2)=O)CCC1
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 376.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Moffett BS, DiSanto AR, Espinosa O, Hou J, Colabuono P. Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets. Clin Pharmacol Drug Dev. 2014 Nov;3(6):493-8. doi: 10.1002/cpdd.129. Epub 2014 Jun 27. PubMed PMID: 27129124. 2: Gómez-Díez M, Muñoz A, Caballero JM, Riber C, Castejón F, Serrano-Rodríguez JM. Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses. Res Vet Sci. 2014 Aug;97(1):105-10. doi: 10.1016/j.rvsc.2014.06.006. Epub 2014 Jun 12. PubMed PMID: 24972864. 3: Kechagia IA, Kalantzi L, Dokoumetzidis A. Extrapolation of enalapril efficacy from adults to children using pharmacokinetic/pharmacodynamic modelling. J Pharm Pharmacol. 2015 Nov;67(11):1537-45. doi: 10.1111/jphp.12471. Epub 2015 Aug 10. PubMed PMID: 26256099. 4: Tarkiainen EK, Tornio A, Holmberg MT, Launiainen T, Neuvonen PJ, Backman JT, Niemi M. Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol. 2015 Nov;80(5):1131-8. doi: 10.1111/bcp.12667. Epub 2015 Jun 11. PubMed PMID: 25919042; PubMed Central PMCID: PMC4631185. 5: Maldonado J, Pereira T, Tavares A. Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal. Drugs R D. 2014 Jun;14(2):147-54. doi: 10.1007/s40268-014-0046-8. PubMed PMID: 24831818; PubMed Central PMCID: PMC4070459. 6: CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 4;316(23):1429-35. PubMed PMID: 2883575. 7: Chompoosan C, Buranakarl C, Chaiyabutr N, Chansaisakorn W. Decreased sympathetic tone after short-term treatment with enalapril in dogs with mild chronic mitral valve disease. Res Vet Sci. 2014 Apr;96(2):347-54. doi: 10.1016/j.rvsc.2014.01.006. Epub 2014 Feb 3. PubMed PMID: 24559801. 8: Pees M, Pees K, Abraham G, Lierz M, Ungemach FR, Krautwald-Junghanns ME. [Examinations on the pharmacokinetics and compatibility of enalapril in racing pigeons]. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2013;41(5):319-25. German. PubMed PMID: 24127029. 9: Burckhardt BB, Tins J, Laeer S. Simultaneous quantitative and qualitative analysis of aliskiren, enalapril and its active metabolite enalaprilat in undiluted human urine utilizing LC-ESI-MS/MS. Biomed Chromatogr. 2014 Dec;28(12):1679-91. doi: 10.1002/bmc.3201. Epub 2014 May 2. PubMed PMID: 24788577. 10: Danafar H, Manjili HK, Najafi M. Study of Copolymer Composition on Drug Loading Efficiency of Enalapril in Polymersomes and Cytotoxicity of Drug Loaded Nanoparticles. Drug Res (Stuttg). 2016 Sep;66(9):495-504. Epub 2016 Jul 19. PubMed PMID: 27434113. 11: SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992 Sep 3;327(10):685-91. Erratum in: N Engl J Med 1992 Dec 10;327(24):1768. PubMed PMID: 1463530. 12: Ramusovic S, Thielking G, Läer S. Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. Biomed Chromatogr. 2012 Jun;26(6):697-702. doi: 10.1002/bmc.1716. Epub 2011 Sep 23. PubMed PMID: 21953651. 13: Antza C, Stabouli S, Kotsis V. Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence. Vasc Health Risk Manag. 2016 Nov 15;12:443-451. eCollection 2016. Review. PubMed PMID: 27895487; PubMed Central PMCID: PMC5118038. 14: Cheregi M, Albu F, Udrescu Ş, Răducanu N, Medvedovici A. Greener bioanalytical approach for LC/MS-MS assay of enalapril and enalaprilat in human plasma with total replacement of acetonitrile throughout all analytical stages. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 15;927:124-32. doi: 10.1016/j.jchromb.2012.11.023. Epub 2012 Nov 30. PubMed PMID: 23266124. 15: Fontana V, Silva PS, Izidoro-Toledo TC, Biagi C, Oliveira EB, Gerlach RF, Tanus-Santos JE. Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension. Cardiovasc Drugs Ther. 2012 Dec;26(6):511-9. doi: 10.1007/s10557-012-6420-2. PubMed PMID: 23085896. 16: Egan CG, Pontremoli R. Role of the fixed-dose combination lercanidipine-enalapril in renal protection. J Nephrol. 2011 Jul-Aug;24(4):428-37. doi: 10.5301/JN.2011.6271. Review. PubMed PMID: 21279953. 17: Arafat T, Awad R, Hamad M, Azzam R, Al-Nasan A, Jehanli A, Matalka K. Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. J Clin Pharm Ther. 2005 Aug;30(4):319-28. PubMed PMID: 15985045. 18: Frost L, Böttcher M, Bøtker HE, Kristensen SD, Nørgaard A. Enalapril and exercise-induced hyperkalemia. A study of patients randomized to double-blind treatment with enalapril or placebo after acute myocardial infarction. Int J Cardiol. 1992 Dec;37(3):401-5. PubMed PMID: 1468826. 19: Ghosh C, Jain I, Shinde CP, Chakraborty BS. Rapid and sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of enalapril and its major metabolite enalaprilat, in human plasma: application to a bioequivalence study. Drug Test Anal. 2012 Feb;4(2):94-103. doi: 10.1002/dta.241. Epub 2011 Feb 21. PubMed PMID: 21341376. 20: Morgan TO, Anderson A. Hemodynamic comparisons of enalapril and felodipine and their combination. Kidney Int Suppl. 1992 May;36:S78-81. PubMed PMID: 1614072.